ReproGo
ReproGo is a pioneering biotechnology company specialising in advanced therapies medicinal products (ATMPs), focusing on stem cell reprogramming, vascular therapeutics, disease modelling, and AI-driven innovations.
The company is dedicated to developing transformative solutions for difficult-to-treat chronic conditions such as chronic wounds i.e. diabetic foot ulcers (DFUs) or other complex wounds.
Our core offerings include:
- Cell Reprogramming: We utilise advanced techniques to transform stem cells into specialised cell types, focusing on repairing and regenerating tissues, particularly for chronic wounds like diabetic foot ulcers.
- Disease Modelling: Our state-of-the-art models, developed from human stem cells, provide accurate simulations of various diseases, enhancing our ability to develop targeted therapies.
- AI-Driven Platform: We are developing an AI platform designed to streamline the development and commercialisation of cell therapies, optimising processes from cell selection to regulatory compliance.
As a multi-award-winning company, ReproGo is recognised for its innovative contributions to biotechnology. Our global engagement and strategic initiatives continue to drive growth and reinforce our role as a leader in the field.
Our mission is to revolutionise healthcare with advanced therapies that repair and regenerate tissues, setting new standards in biotechnology.
2020
Start Date
Belfast
Location
1
Employees
£210k
Grants
£140k
Equity
The Journey
ReproGo, a trailblazer in advanced therapies medicinal products (ATMPs), has made significant strides in the field of stem cell reprogramming and therapeutics, particularly targeting vascular disorders such as chronic wounds and diabetic foot ulcers (DFUs). The company’s journey, marked by prestigious awards and global collaborations, showcases its dedication to advancing healthcare solutions and its growing influence in the biotech industry.
Contact Form
Spin Out
From Queen's University Belfast (QUB)
Prestigious Awards
Totalling to £400k
Expensive Data Collection
(gene & protein expression, single-cell analysis, flow cytometry & more)
Initial Sales £190k
Existing sales and upcoming orders for iPSCs, offering early product validation
Invitations
Invited by Government Regulators (MHRA) & Cell & Gene Therapy Catapult to join a prestigious consortium for a benchmark safety assay in cell therapy
Partnerships
Establishing relationships in: AI, market, product development, validation, cell therapy
What companies had to say about the Innovate UK ICURe programme?
"Our journey with ReproGo began with a commitment to harness the power of stem cells and advanced therapies to address critical unmet needs in vascular health. The support we received from Innovate UK through the ICURe program was pivotal in shaping our early strategy. It allowed us to validate our market approach, leading to further recognition and success. Being named one of the top UK ATMP emerging leaders and participating in global initiatives like the Grand Scale and Global Business Partnership Programs has been both an honor and a testament to our team’s hard work and innovation."
Dr. Sophia Kelaini
CEO at ReproGo
Future Goals
ReproGo is set to introduce an innovative AI-driven platform that will significantly enhance the development and commercialisation of cell therapies. This cutting-edge tool is designed to streamline the entire process – from cell selection to regulatory compliance – offering unprecedented efficiency and cost-effectiveness. In addition, ReproGo will broaden its therapeutic focus beyond chronic wounds, applying its advanced stem cell technologies to address new vascular and complex conditions. The company will also improve its disease modeling capabilities with human stem cells to support drug discovery and therapy development. Key next steps include scaling up operations to increase production and R&D capabilities, strengthening global partnerships, and continuing investment in advanced research to drive progress in stem cell technologies and regenerative medicine.